Hemocompatibility testing for nanomedicines and biologicals: Predictive assays for complement mediated infusion reactions

European Journal of Nanomedicine

Volumn 4, Issue 1, 2012, Pages 33-53

  Szebeni, János ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Adverse drug reactions; Allergy; Antibody; Hypersensitivity; Liposome; Nanoparticles

Indexed keywords

ADVERSE DRUG REACTIONS; ALLERGIC REACTIONS; ANTIBODY THERAPEUTICS; CELLULAR MECHANISMS; CLEAVAGE PRODUCTS; CLINICAL SYMPTOMS; DRUG CARRIER; HEMOCOMPATIBILITY; HYPERSENSITIVITY; HYPERSENSITIVITY REACTION; IMAGING AGENT; IMMUNE SYSTEMS; IN-VITRO; IN-VIVO; MICELLAR SYSTEMS; NANO PARTICULATES; NANOMEDICINES; PATHOGENIC VIRUS; REGULATORY AGENCIES; RISK FACTORS; SAFETY RISKS; SIDE EFFECT; TOXICITY TEST;

ANTIBODIES; ASSAYS; BYPRODUCTS; CELL CULTURE; DECISION TREES; DRUG INTERACTIONS; FUNCTIONAL POLYMERS; LIPOSOMES; NANOPARTICLES; NANOSYSTEMS; PUBLIC RISKS; VIRUSES;

ALLERGIES;

ALEMTUZUMAB; AMPHOCYL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ASPARAGINASE MACROGOL; BEVACIZUMAB; BIOLOGICAL PRODUCT; CETUXIMAB; CYCLOSPORIN; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; ELITEC; ETOPOSIDE; FASTUREC; GEMTUZUMAB OZOGAMICIN; HISTAMINE H2 RECEPTOR; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; LEUKOTRIENE; OMALIZUMAB; PACLITAXEL; PANITUMUMAB; PEGADEMASE; PODOPHYLLOTOXIN; RASBURICASE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TENIPOSIDE; TRASTUZUMAB; TRYPTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERTEPORFIN;

ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC REACTION; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; APNEA; ARTHRALGIA; ASSAY; ASTHENIA; AUTONOMIC DYSFUNCTION; BACKACHE; BASOPHIL; BLOOD ANALYSIS; BLOOD CELL; BLOOD CLOTTING; BLOOD COMPATIBILITY; BLOOD TRANSFUSION REACTION; BRONCHOSPASM; C ACTIVATION RELATED PSEUDOALLERGY; CARDIOGENIC SHOCK; CARDIOVASCULAR DISEASE; CHEST TIGHTNESS; CHILL; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONFERENCE PAPER; COUGHING; CYANOSIS; DIAPHORESIS; DIARRHEA; DIZZINESS; DYSPNEA; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FAINTNESS; FEVER; FOREIGN BODY; GASTROINTESTINAL DISEASE; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HOARSENESS; HOT FLUSH; HUMAN; HYPERTENSION; HYPERVENTILATION; HYPOTENSION; HYPOXIA; IMMUNE SYSTEM; IMMUNOSTIMULATION; INJECTION SITE INDURATION; INJECTION SITE REACTION; LARYNX EDEMA; LARYNX SPASM; LEUKOCYTE ACTIVATION; LUNG DISEASE; LUNG EDEMA; LUNG INFILTRATE; MEDICAL TERMINOLOGY; MICELLE; MOLECULAR SIZE; MOLECULAR WEIGHT; NANOMEDICINE; NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NONHUMAN; PAIN; PHARYNX DISEASE; PREDICTION; PREVALENCE; PRURITUS; RASH; RHINITIS; RHINORRHEA; RIGOR; RISK FACTOR; SERUM SICKNESS; SIDE EFFECT; SKIN DISEASE; STRIDOR; SWELLING; TACHYCARDIA; THORAX PAIN; THROAT TIGHTNESS; THROMBOCYTE ACTIVATION; THROMBOSIS; TONGUE EDEMA; TONGUE SWELLING; TREATMENT INDICATION; UNCONSCIOUSNESS; URTICARIA; VOMITING; WHEEZING;

EID: 84867874461     PISSN: 16625986     EISSN: 1662596X     Source Type: Journal    
DOI: 10.1515/ejnm-2012-0002     Document Type: Conference Paper

References (55)

1. Biological evaluation of medical devices - Part 4: selection of tests for interaction with blood, ANSI/AAMI/ISO 10993-4:2002/(R) 10 March 2009, 2009.
2. Harker LA, Ratner BD, Didisheim P. Cardiovascular biomaterials and biocompatibility. Cardiovasc Pathol 1993;2(Suppl):1S - 224S.
3. Standard Practice for Testing for Alternative Pathway Complement Activation in Serum by Solid Materials, ASTM, publication F2065-00, 1984.
4. Standard Practice for Testing for Whole Complement Activation in Serum by Solid Materials, ASTM F1984-99, 1984.
5. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliver Rev 1997;23:3-25. (Pubitemid 27046991)
6. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-9.
7. Gell PG, Coombs RR. Classification of allergic reactions underlying disease. Oxford: Blackwell, 1963.
8. Coombs RR, Gell PG. Classification of allergic reactions responsible for drug hypersensitivity reactions. In: Coombs RA, Gell PG, editors. Clinical Aspects of Immunology, 2nd ed. Philadelphia, PA: Davis, 1968, p. 575-96.
9. Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncolo Nurs 2010;14:E10-21.
10. Szebeni J. Complement activation-related pseudoallergy: mechanism of anaphylactoid reactions to drug carriers and radiocontrast agents. In: The complement system: novel roles in health and disease. Boston, MA: Kluwer, 2004:399-440.
11. TECOMedical, Complement Diagnostics: Haemocompatibility testing of medical devices, pharmaceuticals and blood products, 2010.
12. Szebeni J, Fontana JL, Wassef NM, Mongan PD, Morse DS, Dobbins DE, et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999;99:2302-9. (Pubitemid 29201138)
13. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization. J Allergy Clin Immunol 2003;113: 832-6. (Pubitemid 38608590)
14. Haxby JA, Kinsky CB, Kinsky SC. Immune response of a liposomal model membrane. Proc Natl Acad Sci US 1968;61:300-7.
15. Haxby JA, Gotze O, Muller-Eberhard HJ, Kinsky SC. Release of trapped marker from liposomes by the action of purified complement components. Proc Natl Acad Sci USA 1969; 64:290-5.
16. Kinsky SC, Haxby JA, Zopf DA, Alving CR, Kinsky CB. Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten. Biochemistry 1969;8: 4149-58.
17. Alving CR, Kinsky SC, Haxby JA, Kinsky CB. Antibody binding and complement fixation by a liposomal model membrane. Biochemistry 1969;8:1582-7.
18. Dervadevics M, Hidvegi T, Schmidt B, Fust G, Varga L. Ragweed allergy: correlation between skin reactivity and in vitro complement activation. Immunol Lett 1998;64:119-23. (Pubitemid 28553021)
19. Barenholz, Y. Doxil - the first FDA-approved nano-drug: from an idea to product. In: Peers D, editor. Handbook of harnessing biomaterials in nanomedicine: preparation, toxicity, and applications. Singapore: Pan Standford Publishing Pte. Ltd., 2012: 335-98.
20. Genovese A, Stellato C, Patella V, Lamparter-Schummert B, de Crescenzo G, Adt M, et al. Contrast media are incomplete secretagogues acting on human basophils and mast cells isolated from heart and lung, but not skin tissue. Eur J Radiol 1994;18(Suppl 1):S61-6.
21. Lieberman P. The use of antihistamines in the prevention and treatment of anaphylaxis and anaphylactoid reactions. Singapore Med J 1989;30:290-3.
22. Lieberman P. Anaphylactoid reactions to radiocontrast materia. Clin Rev Allergy 1991;9:319-38.
23. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. A meta-analysis of prospective studies, J Am Med Assoc 1998;279:1200-5. (Pubitemid 28193431)
24. Demoly P, Kropf R, Bircher A, Pichler WJ. Drug hypersensitivity: questionnaire. EAACI interest group on drug hypersensitivity. Allergy 1999;54:999-1003.
25. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced immune toxicity. Toxicology 2005;216:106-21. (Pubitemid 41712000)
26. Szebeni J, Baranyi L, Sávay S, Bodó M, Milosevits J, Alving CR, et al. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposomeinduced abnormalities in ECG and heart function. Am J Physiol 2006;290:H1050-8.
27. Moghimi SM, Hamad I, Andresen TL, Jörgensen K, Szebeni J. Methylation of the phosphate oxygen moiety of phospholipidmethoxy (polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J 2006;20:2591-3.
28. Szebeni J, Bunger R, Baranyi L, Bedocs P, Toth M, Rosivall L, et al. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles. J Liposome Res 2007;17:107-17. (Pubitemid 47026981)
29. Szebeni J, Moghimi SM. Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions. J Liposome Res 2009;19:85-90.
30. Johnson RA, Simmons KT, Fast JP, Schroeder CA, Pearce RA, Albrecht RM, et al. Histamine release associated with intravenous delivery of a fluorocarbon-based sevoflurane emulsion in canines. J Pharm Sci 2011;100:2685-92.
31. Cavadas M, González-Fernández, Franco R. Pathogen-mimetic stealth nanocarriers for drug delivery: a future possibility. Nanomedicine: Nanotechnology, Biology and Medicine 2011;7:730-43.
32. Szebeni J. The interaction of liposomes with the complement system. Crit Rev Ther Drug Carrier Syst 1998;15:57-88. (Pubitemid 28110564)
33. Szebeni J, Baranyi B, Savay S, Lutz LU, Jelezarova E, Bunger R, et al. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil®), J Liposome Res 2000;10:347-61.
34. Szebeni J, Bedocs P, Rozsnyay Z, Weiszhár Z, Urbanics R, Rosivall L, et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine NBM 2012;8:176-84.
35. Chanan-Khan A, Szebeni J, Savay S, Liebes L, Rafique NM, Alving CR, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003;14: 1430-7. (Pubitemid 37185291)
36. Szebeni J, Muggia F, Gabizon G, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipientbased therapeutic products: prediction and prevention. Adv Drug Deliver Rev 2011;63:1020-30.
37. Hastings KL. Implications of the new FDA/CDER immunotoxicology guidance for drugs. Int Immunopharmacol 2002;11: 1613-8. (Pubitemid 35223242)
38. Data Requirements for Intravenous Liposomal Products Developed with Reference to an Innovator Liposomal Product, 2011.
39. Szebeni J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents. Crit Rev Ther Drug Carr Syst 2001;18:567-606. (Pubitemid 34024397)
40. Mollnes TE, Brekke OL, Fung M, Fure H, Christiansen D, Bergseth G, et al. Essential role of the C5a receptor in E coliinduced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002;100:1869-77. (Pubitemid 34925168)
41. Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998;90: 300-6. (Pubitemid 28182386)
42. Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A, Danino D, et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Intern Immunopharm 2001;1:721-35. (Pubitemid 32206533)
43. Weiszhár Z, Czúcz J, Révész C, Rosivall L, Szebeni J, Rozsnyay Z. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci 2012;45:492-8.
44. Szebeni J, Baranyi L, Götze O, Alving CR, Bünger R, Mongan PD. Complement activation during hemorrhagic shock and resuscitation in swine. Shock 2003;20:347-55.
45. Szebeni J, Baranyi B, Savay S, Bodo M, Morse DS, Basta M, et al. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol 2000;279:H1319-28.
46. Boumiza R, Monneret G, Forissier MF, Savoye J, Gutowski MC, Powell WS, et al. Marked improvement of the basophil activation test by detecting CD203c instead of CD63. Clin Exp Allergy 2003;33:259-65. (Pubitemid 36241385)
47. Boumiza R, Debard AL, Monneret G. The basophil activation test by flow cytometry: recent developments in clinical studies, standardization and emerging perspectives. Clin Mol Allergy 2005;3:9.
48. Monneret G, Boumiza R, Gendt L, Debard AL. The basophil activation test by flow cytometry: recent improvements and emerging perspectives. Toxicology 2005.
49. Winkler GC. Pulmonary intravascular macrophages in domestic animal species: review of structural and functional properties. Am J Anat 1988;181:217-34.
50. Merkel O, Urbanics R, Bedocs P, Rozsnyay Z, Rosivall L, Toth M, et al. In vitro and in vivo complement activation and related anaphylactic effects associated with polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers. Biomaterials 2011;32:4936-42.
51. Szebeni J, Bedocs P, Urbanics R, Bünger R, Rosivall L, Tóth M, et al. Prevention of infusion reactions to PEGylated liposomal doxorubicin via tachyphylaxis induction by placebo vesicles: a porcine model. J Contr Rel 2012, doi:10.1016/j.jconrel.2012.02.029 .
52. Szebeni J, Barenholz Y. Complement activation, immunogenicity, and immune suppression as potential side effects of liposomes. In: Peer Pan D, editor. Handbook of Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications: Stanford Publishing Pte. Ltd., Singapore. 2012:311-35.
53. Hugli TE, Morgan EL. Mechanisms of leukocyte regulation by complement-derived factors. Contemp Top Immunobiol 1984;14:109-53.
54. Hugli TE. Structure and function of anaphylatoxins. Spring Semin Immunopathol 1984;7:193-219.
55. Marceau F, Lundberg C, Hugli TE. Effects of anaphylatoxins on circulation. Immunopharmacol 1987;14:67-84.